OBJECT: Symptomatic intracranial arterial stenoses have a high rate of recurrent stroke despite medical and endovascular treatments. The authors present clinical and angiographic quantitative outcomes of indirect revascularization for patients with symptomatic intracranial stenosis. METHODS: Patients treated for symptomatic intracranial arterial stenosis by indirect revascularization were included. The patient population comprised those in whom medical management had failed and for whom endovascular therapy was unsuitable or had failed. Patients underwent encephaloduroarteriosynangiosis (EDAS) with or without bur holes. Preoperative and postoperative angiograms were evaluated for change in caliber of extracranial blood vessels (superficial temporal artery [STA] and middle meningeal artery [MMA]) and for evidence of neovascularization. RESULTS: Thirteen patients underwent EDAS. Ischemic symptoms ceased within the follow-up period in all patients, returning in a delayed fashion in only 2. No other patients had recurrent TIAs or strokes after the initial postoperative period. Donor blood vessels increased in size relative to preoperative sizes in all but 1 case (average increase of 52% for proximal STA [p=0.01], 74% for midpoint of STA [p=0.01], and 84% for the MMA [p=0.02]). In addition, 8 of 11 patients demonstrated direct spontaneous anastomoses from extracranial to middle cerebral artery branches, and all patients demonstrated angiographic evidence of vascular blush and/or new branches from the STA and/or MMA. CONCLUSIONS: Indirect revascularization appears to be a safe and effective method to improve blood flow to ischemic brain due to intracranial arterial stenosis. Neovascularization and enlargement of the branches of the ECA were observed in all patients and correlated with improvement in ischemic symptoms. Indirect revascularization is an option for patients in whom medical therapy has failed and who are not suitable for endovascular treatment.
OBJECT: Symptomatic intracranial arterial stenoses have a high rate of recurrent stroke despite medical and endovascular treatments. The authors present clinical and angiographic quantitative outcomes of indirect revascularization for patients with symptomatic intracranial stenosis. METHODS:Patients treated for symptomatic intracranial arterial stenosis by indirect revascularization were included. The patient population comprised those in whom medical management had failed and for whom endovascular therapy was unsuitable or had failed. Patients underwent encephaloduroarteriosynangiosis (EDAS) with or without bur holes. Preoperative and postoperative angiograms were evaluated for change in caliber of extracranial blood vessels (superficial temporal artery [STA] and middle meningeal artery [MMA]) and for evidence of neovascularization. RESULTS: Thirteen patients underwent EDAS. Ischemic symptoms ceased within the follow-up period in all patients, returning in a delayed fashion in only 2. No other patients had recurrent TIAs or strokes after the initial postoperative period. Donor blood vessels increased in size relative to preoperative sizes in all but 1 case (average increase of 52% for proximal STA [p=0.01], 74% for midpoint of STA [p=0.01], and 84% for the MMA [p=0.02]). In addition, 8 of 11 patients demonstrated direct spontaneous anastomoses from extracranial to middle cerebral artery branches, and all patients demonstrated angiographic evidence of vascular blush and/or new branches from the STA and/or MMA. CONCLUSIONS: Indirect revascularization appears to be a safe and effective method to improve blood flow to ischemic brain due to intracranial arterial stenosis. Neovascularization and enlargement of the branches of the ECA were observed in all patients and correlated with improvement in ischemic symptoms. Indirect revascularization is an option for patients in whom medical therapy has failed and who are not suitable for endovascular treatment.
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: David S Liebeskind; George A Cotsonis; Jeffrey L Saver; Michael J Lynn; Tanya N Turan; Harry J Cloft; Marc I Chimowitz Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Randall T Higashida; Anthony J Furlan; Heidi Roberts; Thomas Tomsick; Buddy Connors; John Barr; William Dillon; Steven Warach; Joseph Broderick; Barbara Tilley; David Sacks Journal: Stroke Date: 2003-07-17 Impact factor: 7.914
Authors: Salina P Waddy; George Cotsonis; Michael J Lynn; Michael R Frankel; Seemant Chaturvedi; Janice E Williams; Marc Chimowitz Journal: Stroke Date: 2008-10-02 Impact factor: 7.914
Authors: Adnan I Qureshi; Edward Feldmann; Camilo R Gomez; S Claiborne Johnston; Scott E Kasner; Donald C Quick; Peter A Rasmussen; M Fareed K Suri; Robert A Taylor; Osama O Zaidat Journal: J Neuroimaging Date: 2009-10 Impact factor: 2.486
Authors: A N Laiwalla; F Kurth; K Leu; R Liou; J Pamplona; Y C Ooi; N Salamon; B M Ellingson; N R Gonzalez Journal: AJNR Am J Neuroradiol Date: 2017-01-19 Impact factor: 3.825
Authors: Tanya N Turan; Osama O Zaidat; Gary S Gronseth; Marc I Chimowitz; Antonio Culebras; Anthony J Furlan; Larry B Goldstein; Nestor R Gonzalez; Julius G Latorre; Steven R Messé; Thanh N Nguyen; Rajbeer S Sangha; Michael J Schneck; Aneesh B Singhal; Lawrence R Wechsler; Alejandro A Rabinstein; Mary Dolan O'Brien; Heather Silsbee; Jeffrey J Fletcher Journal: Neurology Date: 2022-03-22 Impact factor: 9.910